The levels of these molecules in the CSF are insufficient for them to be utilized as biomarkers, but the recent AD Neuroimaging Initiative study indicated that CSF β-amyloid and tau protein analysis combined with neuroimaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) may provide reliable information for early diagnosis and tracking of severity in AD [3]. This evidence concerns the gene MAPT and Alzheimer disease.